Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | NPC1 | O15118 | 5/20 | 1.00 |
| ▸ | RAB9A | P51151 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.80 |
| ▸ | MEN1 | O00255 | 1/20 | 0.80 |
| ▸ | LMNA | P02545 | 1/20 | 0.80 |
| ▸ | HPGD | P15428 | 1/20 | 0.80 |
| ▸ | MAOA | P21397 | 3/20 | 0.75 |
| ▸ | MAOB | P27338 | 3/20 | 0.75 |
| ▸ | ATM | Q13315 | 2/20 | 0.74 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.70 |
| ▸ | STAT3 | P40763 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15404139 | 1.00 | MAPT (1.00) | MAPTNPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL4728397 | 0.90 | STAT3 (0.84) | MAPTNPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL4728402 | 0.90 | STAT3 (0.84) | MAPTNPC1RAB9AALDH1A1SMN1; SMN2 | |
| Chalcone SCHEMBL25195107 | 0.89 | MAPT (0.80) | MAPTNPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL28553855 | 0.88 | MAPT (0.79) | MAPTNPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL108665 | 0.88 | MAPT (0.79) | MAPTNPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL28549142 | 0.86 | MAOA (0.76) | MAPTNPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL5147081 | 0.85 | MAPT (0.84) | MAPTNPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL30382530 | 0.85 | MAPT (0.84) | MAPTNPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL7996466 | 0.85 | MAPT (0.84) | MAPTNPC1RAB9AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307381-B1 | NEW DRUGS FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) | 2021-01-13 | — | — | EP | disclosed |
| EP-2307381-B1 | NEW DRUGS FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) | 2021-01-13 | — | — | EP | disclosed |
| EP-2687513-B1 | DRUGS FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) | 2020-12-02 | — | — | EP | disclosed |
| US-10435373-B2 | Drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases | LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) | 2019-10-08 | — | — | US | disclosed |
| EP-2684873-B1 | DRUGS FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) | 2019-01-16 | — | — | EP | disclosed |
| US-20180346426-A1 | DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) | 2018-12-06 | — | — | US | disclosed |
| US-10071966-B2 | Drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases | LUDWIG-MAXIMALIANS-UNIVERSITAT MUNCHEN (DE) | 2018-09-11 | — | — | US | disclosed |
| CN-105968084-A | 3',4'-methylenedioxy chalcone derivatives, as well as preparation method and application thereof to tumor suppression | 哈尔滨医科大学 | 2016-09-28 | — | — | CN | disclosed |
| CN-105968084-A | 3',4'-methylenedioxy chalcone derivatives, as well as preparation method and application thereof to tumor suppression | 哈尔滨医科大学 | 2016-09-28 | — | — | CN | disclosed |
| US-20160185730-A1 | DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) | 2016-06-30 | — | — | US | disclosed |
| US-20160185730-A1 | DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) | 2016-06-30 | — | — | US | disclosed |
| US-20160185730-A1 | DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) | 2016-06-30 | — | — | US | disclosed |
| EP-2687513-A1 | Drugs for inhibiting aggregation of proteins invoved in diseases linked to protein aggregation and/or neurodegenerative diseases | Ludwig-Maximilians-Universität München (DE) | 2014-01-22 | — | — | EP | disclosed |
| EP-2684873-A1 | DRUGS FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | Ludwig-Maximilians-Universität München (DE) | 2014-01-15 | — | — | EP | disclosed |
| US-20110293520-A1 | NEW DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. | 2011-12-01 | — | — | US | disclosed |
| US-20110293520-A1 | NEW DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. | 2011-12-01 | — | — | US | disclosed |
| US-20110293520-A1 | NEW DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. | 2011-12-01 | — | — | US | disclosed |
| WO-2010000372-A2 | NEW DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185730-A1 | DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | PARK7, APP, HYPK | MAPT 8/4885NPC1 363/4885RAB9A 1574/4885 |
| US-10071966-B2 | Drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases | PARK7, APP, HYPK | MAPT 8/4885NPC1 363/4885RAB9A 1574/4885 |
| US-20110293520-A1 | NEW DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | PARK7, HYPK, IK | MAPT 40/4885NPC1 339/4885RAB9A 954/4885 |
| US-20180346426-A1 | DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | PARK7, APP, HYPK | MAPT 8/4885NPC1 363/4885RAB9A 1574/4885 |
| US-10435373-B2 | Drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases | PARK7, APP, HYPK | MAPT 8/4885NPC1 363/4885RAB9A 1574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.